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Summary.-Aprotinin was bound and endocytosed by Landschutz ascites carcinoma
(LAC) cells in vitro. Addition ofthe antiprotease to cultures of these cells led to a dose-
dependent growth-inhibitory and cytotoxic effect. In mice inoculated with LAC cells
and treated with aprotinin there was a transient reduction in both the number and
concentration of recovered ascites cells during the early phase of tumour growth.
This was accompanied by a temporary increase in the proportion of peritoneal
phagocytes (mononuclear phagocytes and polymorphonuclear leucocytes) relative
to carcinoma cells. However, the number and concentration of ascites cells eventually
achieved was comparable in saline and aprotinin-treated animals.
THE low-molecular-weight polypeptide
aprotinin (Trasylol) which is isolated
from bovine lung, binds specifically
to sialyl residues, and has been used to
demonstrate their presence on the surfaces
of a variety of animal cells (Kiernan and
Stoddart, 1973) including human lympho-
cytes (Stoddart et al., 1974). In addition to
its carbohydrate-binding properties, apro-
tininisabroad-spectrumantiproteasewhich
inhibits the enzymes trypsin, chymotryp-
sin and plasma kallikrein (Werle, 1970).
Ofthe wide range ofnaturally-occurring
and synthetic protease inhibitors currently
available, some, including aprotinin, im-
pair the growth of malignant cells and
their non-malignant homologues in vitro
(Coetz et al., 1972; Latner et al., 1973;
Roblin et al., 1975). Thus, although the
original claim of Schnebli and Burger
(1972) that the growth-inhibitory effects
of protease inhibitors are directed selec-
tively against malignant tumour cells, has
not beeni suibstantiated (Hynes, 1 976;
Schuiebli, 1975) nevertheless, inhibition of
maligniant cell growth by protease inhibi-
tors lends to the view (Bosmann and Hall;
1974; Easty and Easty, 1976; Hynes,
1976; Schnebli, 1975; Sylven, 1967) that
tumour cell proteases potentiate the
growth of malignant tumours. However,
evaluation of aprotinin as an anti-tumour
agent in vivo by various authors has pro-
duced variable results (Back et al., 1966;
Back and Steger, 1976; Cliffton and Agos-
tino, 1964; Giraldi et al., 1977; Latner et
al., 1974; Thomson et al., 1977).
In this study, we have used an indirect
immunoperoxidase technique to examine
the binding of aprotinin by Landschuitz
ascites carcinoma (LAC) cells. Also, in
view of reports that a natural protease in-
hibitor (soybean trypsin inhibitor) im-
pairs growth of ascites tumours (Whur et
al., 1973; Verloes et al., 1978) we have
attempted to determiine whether aprotinin
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exerts similar effects against LAC in vitro
and in vivo.
MATERIALS AND METHODS
Mice.-Closed-colony bred, 5-8-week-old,
female LACA mice, ranging in weight from 17
to 24 g were used throughout.
Aprotinin.-Aprotinin (Trasylols) was
supplied as a solution (1.5 mg/ml, in 0-9%
w/v aqueous NaCl) as marketed for clinical
use by Bayer Pharmaceuticals, Haywards
Heath, Sussex at an activity of 10,000 kalli-
krein-inactivating units (KIU) per ml.
Tumour cells.-The non-strain-specific
Landschiitz ascites tumour, a subline of the
Ehrlich diploid carcinoma (Tjio and Levan,
1954) was propagated byi.p. passagein female
LACA mice. Cells aspirated from the perito-
neal cavity on the 7th day oftumour develop-
ment were washed x 3 in ice-cold Eagle's
minimal essential medium (MEM; Wellcome
Reagents Limited) and cell viability assessed
by trypan-blue exclusion prior to injection.
Binding ofaprotinin.-Washed ascites cells
were cultured within Falcon tissue-culture
flasks (Flow Laboratories) in MEM supple-
mented with 10% foetal bovine serum (Gibco
Bio-Cult) for 4 h at 37°C in an atmosphere of
5% CO2 in air. They were then either fixed in
2.5% glutaraldehyde before incubation for 1
h in aprotinin (10,000 KIU/ml) at 20°C, or
alternatively, incubated in aprotinin-contain-
ing medium (5,000 KIU/ml) and then fixed
in glutaraldehyde. In each instance the
treated, washed cells were further incubated,
firstwithrabbit anti-aprotinin antibody (1: 10;
Thomson et al., 1978) and then, following
several rinses in phosphate buffer, with peroxi-
dase-conjugated goat anti-rabbit serum
(Dakopatts A/S). The cytochemical procedure
of Graham and Karnovsky (1966) was used
to reveal the sites of cell-bound peroxidase-
conjugated antibody and the cells then post-
fixed for 1 h at 4°C in 1% osmium tetroxide,
followed by dehydration in graded ethanols
and embedding in TAAB epoxy resin. Ultra-
thin sections were stained in uranyl acetate
(Watson, 1958) and lead citrate (Reynolds,
1963) prior to examination in an AEI EM6B
transmission electron microscope.
In vitro growth and viability studies.-Two
dilutions of aprotinin (5 and 125 KIU) were
added to cultures of ascites cells (2 x 105 cells
in 0-2 ml) in MEM supplemented with 10%
heat-inactivated foetal bovine serum within
flat-bottomed microcultures plates (3040 Fal-
con Plastics). Each treatment was replicated
6 times. At 24 and 48 h the culture super-
natants were replaced by fresh medium con-
taining equivalent doses of aprotinin to those
added at the start ofthe culture. Cell numbers
were estimated by haemocytometry and via-
bility assessed by trypan-blue exclusion at
24, 48 and 72 h.
In vivo experiments.-Growth of the tu-
mour was measured in animals injected with
106 viable ascites cells. Each group received
either 0 5 ml aprotinin (5,000 KIU) or an
equivalent volume of Dulbecco "A" phos-
phate buffered saline (PBS) i.p. at the same
time as tumour injection and twice daily
thereafter. At various times after cell chal-
lenge 12 mice, 6 from each treatment group,
were killed and growth measurements con-
ducted.
Monitoring of tumour growth.-Mice were
killed by terminal ether anaesthesia. At early
stages of tumour development (Days 2 and 4)
when there was little measurable ascitic fluid,
free ascites cells were removed by lavaging
the peritoneal cavity with 10 ml PBS con-
taining heparin (2 IU/ml). At later stages, a
midline incision was made in the abdominal
wall, the ascitic fluid withdrawn and placed
in a pre-weighed test tube. The remaining
fluid was removed by swabbing the peritoneal
cavity with pre-weighed cotton wool. Since
the sp. gr. ofascitic fluid approximates closely
to 1 (Wheatley and Ambrose, 1964) theweight
of fluid (measured correct to 10-3 g) corre-
sponded to the volume (ml) of fluid present.
Confirmation of ascitic-fluid volume was
achieved by weighing the mice (correct to
10-2 g) before and after removal of the
tumour. Total free ascites cells was then given
by the product ofascitic fluid volume and the
cell count per ml, which, together with cell
viability was estimated by haemocytometry.
Characterization of peritoneal cells.-Peri-
toneal cavities of mice injected i.p. with
tumour cells, and either aprotinin or saline,
were lavaged withheparin-containingmedium
and the aspirates centrifuged to obtain cell
pellets which were fixed in glutaraldehyde
followed by osmium tetroxide and then em-
bedded in TAAB epoxy resin. Cytodiagnostic
observations on the cells within the pellets
together with counts ofthe different cell types
present, were made on 1 ,um sections stained
with toluidine blue.
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FIG. 1 -Glutaraldehyde-fixed LAC cell stained by the indirect immunoperoxidase procedure to
reveal binding of aprotinin to the cell surface. x 8,500. Inset: detail, showing positive staining for
aprotinin bound to the outer osmiophilic leaflet of the plasma membrane. x 50,000.
RESULTS
Binding of aprotinin
Using the indirect immunoperoxidase
staining procedure to localise cell-bound
aprotinin, an electron-dense precipitate
was observed at the surfaces of LAC cells
which had been fixed in glutaraldehyde
prior to incubation in the protease inhibi-
tor (Fig. 1). The electron-dense precipitate
which was some 30-50 nm wide, was ad-
herent to the outer osmiophilic "leaflet"
(zone?) ofthe plasma membrane, revealing
that aprotinin had bound to moieties in
the glycocalyx region of the tumour-cell
surface (Inset, Fig. 1). There was no sur-
face staining visible on those cells which
had not been incubated in aprotinin prior
to the indirect immunoperoxidase staining.
Ultrastructural studies on LAC cells
which had been incubated in medium con-
taining aprotinin prior to fixation and in-
direct immunoperoxidase staining (Fig. 2)
revealed not only binding of aprotinin to
the surface membranes ofthe tumour cells,
but also the presence of numerous posi-
tively stained intracellular vermiform can-
aliculi, vesiclesandvacuoles (Insets,LFig. 2)
which indicated that the tumour cells had
endocytosedaprotinin, afactorwhichprob-
ably accounts for the relatively patchy
distribution of the surface staining for
aprotinin observed on these cells compared
with that observed on the surfaces of the
glutaraldehyde-prefixed ascites tumour
cells.
Effect of aprotinin on cell growth and
viability in vitro
Fig. 3 shows the growth and viability of
ascites cells cultured in the presence of
aprotinin. A dose-dependent cytotoxic and
growth-inhibitory effect was observed
after 24, 48 and 72 h. Addition of 125 KIU
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immunoperoxidase procedure. Note patchy distribution ofaprotinin on the plasma membrane, and
endocytosis of aprotinin (arrows) as revealed by the presence of positively stained canaliculi,
vesicles and vacuoles. Main Fig. and Insets x 25,000.
aprotinin completely impaired growth and
caused marked reduction in cell viability.
Cellular disintegration accounted for the
observed reduction in numbers of intact
cells within the cultures with 125 KIU
aprotinin.
Effect8 of aprotinin on tumour growth
G-rowth ofthe tumour, measured by the
number of recoverable ascites cells within
both saline and aprotinin-treated animals
at various times afterinjection of106viable
tumour cells is shown in Fig. 4. There was
an exponential increase in recoverable
cells, over the first 9 days after cell injec-
tion, a maximum of r--109 tumour cells
being attained by Day 12 in both saline
and aprotinin-treated mice. However,
aprotinin treatment resulted in a signifi-
cant reduction in the total number of
ascites cellsrecovered onDay2 (P<0.0005)
and Day 4 (P<0.025). No statistically sig-
nificant difference in the number of re-
coverable cells between aprotinin and
saline-treated groups ofmice was observed
at any other time. The viability of ascites
cells recovered from all animals was found
by dye-exclusion studies to exceed 95%.
The volume of ascitic fluid and the in
vivo concentration of tumour cells at
various times after tumour challenge are
shown in Figs. 5 and 6 respectively. There
was little ascitic-fluid production prior to
Day 4, after which there was a rapid in-
crease to a mean volume of 8 ml on Days
10-12. No statistically significant differ-
ence was found in ascitic-fluid volume be-
tween aprotinin and saline-treated mice.
However, by virtue ofthe lower number of
cells recovered from aprotinin-treated mice
on Days 2 and 4, there was a significant
reduction in the cell concentration within
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FIG. 3.-Growth and viability of LAC cells cultured for various periods in the presence of aprotinin.
Aprotinin-supplemented and control media were refreshed at 24 and 48 h. Each point represents the
mean of 6 cultures±s.d. (O), 0; (I), 5; (A) 125 KIU per culture.
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FIG. 4.-Number ofperitoneal cells recovered
from mice at various times after injection
of LAC. Animals received twice-daily in-
jections of saline (DO) or aprotinin (*).
Each point represents a single mouse.
this group on these days. The concentra-
tion in both groups rose to around 108 cells
per ml within 7 days ofinjection, and was
maintained at this level for the remainder
of the experiment.
Effect of aprotinin on peritoneal cell
populations
In view of the observed effect of apro-
tinin during the initial stages of tumour
growth, peritoneal cavities ofanimals were
lavaged 2, 4 and 6 days after cell challenge
and the morphological characteristics of
the resident cells investigated. It was
found that on Days 2 and 4 aprotinin
treatment caused a reduction in the pro-
portion of carcinoma cells and increased
_j the incidence of host phagocytic cells
12 (mononuclear phagocytes and polymor-
phonuclear leucocytes) within the perito-
neum. The incidence ofdamaged cells, first
detected on Day 4, was increased in apro-
tinin-treated mice. A further notable
feature was that mast cells were evident
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FiG. 6.- Concentration of cells in ascitic fluid
obtainecl from mice at various times after
injection of LAC. Each point represents a
single mouse. (DO) saline treated; (*)
aprotiiiin treate(l.
Days after tumour cell injection
FIG. 5.-Volume of ascitic fluid recoveredl
from inice at various times after injection
of LAC. Each point represents the mean
-s.(l. for groups of 6 animals. (O), saline
treated; (*) aprotinin treate(l.
in peritoneal lavages from aprotinin-
treated animals on Day 2.
DISCIUSSION
Several authors have reported impaired
growth of ascites tumours using synthetic
and naturally-occurring antiproteases
other than aprotinin, in studies which have
recognized the importance of enzyme
systems in malignant-growth regulation
(Back and Leblanc, 1977; Kinjo et al.,
1963; Verloes et al., 1978; Whur et al.,
1973). In this study, we have shown that
the sialic-acid-binding protein and broad-
spectrum antiprotease aprotinin, although
mediating an anti-tumour effect in vitro,
has only a short-lived effect on the initial
s
phase of growth of an ascites tumour in
vivo.
We have confirmed, at the ultrastruc-
tural level, that aprotinin binds to cell
surfaces, and have shown that ascites cells
cultured in the presence of the antipro-
tease endocytose membrane-bound apro-
tinin. Presumably, aprotinin-treated cells
endosomes containing the antiprotease
fuse with primary lysosomes, thereby
inactivating neutral proteases. Such a
mechanism could account for the dose-
dependent growth-inhibitory effect ex-
erted by aprotinin on cultured LAC cells,
due to inhibition of protease-dependent
metabolic pathways; further studies to
elucidate the effects of aprotinin on LAC
cell metabolism are currently in progress.
In addition, however, membrane-bound
aprotinin could readily antagonize pro-
tease activity at the cell surface, a
phenomenon which may stimulate cell
growth (Hynes, 1976; Talmadge et al.,
1974). In vtio however, such effects are
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likely to be less pronounced, due to more
rapid catabolism of aprotinin and its
widespread binding to ubiquitous sialyl
moieties; factors which probably account
for its relative inefficiency as a therapeutic
agent in the tumour-bearing host, and
which are likely to be exaggerated by
rapid cell replication and copious ascitic
fluid production.
The transient anti-tumour effect ob-
served in vivo, as evidenced by reduced
cell numbers and an increased proportion
of host phagocytic cells, could reflect a
cytotoxic effect of the drug accompanied
by stimulation of the temporary reticulo-
endothelial response to the tumour (El
Hassan and Stuart, 1965). Indeed, Latner
and Turner (1976) have claimed that apro-
tinin does influence the host's immune re-
sponse during tumour growth. Using com-
parable treatment regimes to that used in
the present study, Latner et al. (1974) and
Back and Steger (1976) were able to
demonstrate a clear inhibitory effect of
aprotinin against growth of solid murine
tumours. It is our opinion that ascitic
tumours such as LAC may provide a less
favourable milieu for full expression ofthe
anti-tumour potential of this naturally-
occurring antiprotease.
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